BioRestorative Therapies Inc
BRTX
NASDAQ
Biotechnology
$0.23
USD
+0.01 (+2.59%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $5.61M
Volume 160.3K
Revenue
$357,870
TTM
-8.5%
YoY
Gross Margin
92%
TTM
+0.0%
YoY
Net Income
$-11.06M
TTM
+8.6%
YoY
Operating Cash Flow
$-11.82M
TTM
-36.0%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.3 | 0.0 | 0.0 | 0.0 |
YoY Growth | -28.6% | +240.4% | -94.9% | -54.7% | -7.3% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.3 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 2.2 | 1.4 | 1.1 | 1.2 | 1.5 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 4.8 | 3.6 | 3.7 | 3.8 | 3.4 |
Operating Income | -4.8 | -3.3 | -3.7 | -3.8 | -3.4 |
EBITDA | -4.8 | -3.3 | -3.7 | -3.8 | -3.3 |
Other Income / Expense | -0.6 | 0.6 | 0.6 | 0.6 | 1.2 |
Total Other Income / Expense | -0.5 | 0.6 | 0.7 | 0.6 | 1.2 |
Income Before Income Taxes | -5.3 | -2.7 | -3.0 | -3.2 | -2.2 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -5.3 | -2.7 | -3.0 | -3.2 | -2.2 |
Consolidated Net Income / Loss | -5.3 | -2.7 | -3.0 | -3.2 | -2.2 |
Net Income Attributable to Common Shareholders | -5.3 | -2.7 | -3.0 | -3.2 | -2.2 |
Basic EPS | -$0.64 | -$0.30 | -$0.33 | -$0.33 | -$0.12 |
Diluted EPS | -$0.64 | -$0.30 | -$0.33 | -$0.33 | -$0.12 |
Basic Shares Outstanding | 8.4M | 8.7M | 9.1M | 9.8M | 17.7M |
Diluted Shares Outstanding | 8.4M | 8.7M | 9.1M | 9.8M | 17.7M |